Glycoprotein cancer biomarker
AssigneeUniversity of Georgia Research Foundation, Inc.
InventorsJames Michael Pierce, Karen L. Abbott
Life of this patent
Estimating the term…
Abstract
The invention relates to glycoproteins having a cancer-specific glycoform. Cancer-specific glycoforms are useful in diagnostics and therapeutics.
Claims28
A multiplexed method for evaluating the presence, absence, nature or extent of breast cancer or a precancerous condition of the breast, the method comprising:
- providing a biological sample obtained from a subject, the biological sample comprising glycoproteins;
- and
- for each of a plurality of glycoproteins in the sample, determining the presence, absence or amount of a cancer-specific glycoform of the glycoprotein, said cancer-specific glycoform comprising a glycan indicative of breast cancer or a precancerous condition of the breast;
- wherein the plurality of glycoproteins are selected from the group consisting of periostin (POSTN), osteoglycin (mimecan;
- OGN), haptoglobin-related protein (HPR), apo-A1 precursor (APOA-1), collagen VI α3 (COL6A3), collagen α1 VI chain precursor (COL6A1), collagen α1 VI isoform 2C2 (COL6A2), tubulin α6 (TUBA1C), variable Ig (IGLV4-3), triosphosphate iso (TPI1), α-1 antitrypsin inhibitor (SERPINA1), vimentin-like 50 kDA (VM), or 14-3-3-zeta protein (KCIP-1);
- and
- wherein the presence, absence or amount of the cancer-specific glycoform is indicative of the presence, absence, nature or extent of breast cancer or a precancerous condition of the ovary.
A method for evaluating the presence, absence, nature or extent of breast cancer or a precancerous condition of the breast, the method comprising:
- detecting the presence of a cancer-specific glycoform of a glycoprotein in a biological sample obtained from a subject, wherein the cancer-specific glycoform comprises a glycan indicative of the presence of cancer or a precancerous condition;
- and wherein the glycoprotein is selected from the group consisting of periostin (POSTN), osteoglycin (mimecan;
- OGN), and 14-3-3-zeta protein (KCIP-1).
An isolated cancer-specific glycoform of periostin comprising a GlcNAc β(1,6) Man branched N-linked glycan component.
An isolated cancer-specific glycoform of osteoglycin comprising GlcNAc β(1,6) Man branched N-linked glycan component.
A multiplexed method for evaluating the presence, absence, nature or extent of ovarian cancer or a precancerous condition of the ovary, the method comprising:
- providing a biological sample obtained from a subject, the biological sample comprising glycoproteins;
- and
- for each of a plurality of glycoproteins in the sample, determining the presence, absence or amount of a cancer-specific glycoform of the glycoprotein, said cancer-specific glycoform comprising a glycan indicative of ovarian cancer or a precancerous condition of the ovary;
- wherein the plurality of glycoproteins are selected from the group consisting of periostin (POSTN), biglycan (BGN), heparan sulfate proteoglycan 2 (HSPG2), lactate dehydrogenase A (LDHA), thrombospondin 1 (THBS1) serine protease inhibitor H1 (SERPINH1), lysosomal-associated membrane glycoprotein 1 (LAMP1), lectin galactosidase soluble binding protein 3 (LGALS3BP), complement factor B (CFB), fibulin 5 (FBLN5), mucin 5b (MUC5b), and lactotransferrin (LTF);
- and
- wherein the presence, absence or amount of the cancer-specific glycoform is indicative of the presence, absence, nature or extent of ovarian cancer or a precancerous condition of the ovary.
A method for identifying a biomarker associated with cancer comprising:
- providing a test sample obtained from a subject having cancer or a precancerous condition or from a cancer cell culture, wherein the test sample comprises a cancer-specific glycoform of a glycoprotein comprising a glycan;
- and
- contacting the test sample with a glycan-binding molecule specific for the glycan, under conditions that permit binding of the cancer-specific glycoform of the glycoprotein to the glycan-binding molecule to yield a bound glycoprotein/glycan-binding molecule complex.
Dependencies are inferred from the claim text.